|
|
ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease
Sources News Release
http://www.sources.com/Releases/NR1292.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 26/05/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
Abstract: Hoboken, NJ – May 23, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial dose step, the Safety Review Committee for ANAVEX 2-73 unanimously approved skipping the 5 mg dose and moving directly to the 10 mg dose step. The next group of eight he...
To read the full release go to http://www.sources.com/Releases/NR1292.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
